Provided by Tiger Trade Technology Pte. Ltd.

Enanta Pharmaceuticals

12.08
-0.5700-4.51%
Post-market: 12.080.00000.00%16:05 EDT
Volume:114.44K
Turnover:1.39M
Market Cap:350.54M
PE:-3.91
High:12.54
Open:12.51
Low:12.04
Close:12.65
52wk High:17.15
52wk Low:4.09
Shares:29.02M
Float Shares:20.83M
Volume Ratio:0.80
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0871
EPS(LYR):-3.8381
ROE:-60.01%
ROA:-13.47%
PB:2.77
PE(LYR):-3.15

Loading ...

Enanta Pharmaceuticals Inc - Prices Upsized Offering of 6,500,000 Shares at $10.00 Each

THOMSON REUTERS
·
Oct 01, 2025

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

THOMSON REUTERS
·
Oct 01, 2025

Enanta Pharmaceuticals Announces $50 Million Public Offering of Common Stock, with Option for Additional $7.5 Million

Reuters
·
Oct 01, 2025

Enanta Pharmaceuticals Is Maintained at Buy by WestPark Capital

Dow Jones
·
Sep 30, 2025

Enanta Pharmaceuticals Inc : Leerink Partners Raises Target Price to $9 From $7

THOMSON REUTERS
·
Sep 30, 2025

Enanta's RSV Pill Shows Promise In Cutting Recovery Time For High-Risk Adults

Benzinga_recent_news
·
Sep 30, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Rare Earth, Copper miners, Gold miners

Reuters
·
Sep 29, 2025

Enanta Pharmaceuticals Announces Positive Phase 2b RSV Study Results

TIPRANKS
·
Sep 29, 2025

Enata Doesn't Meet Primary Endpoint in RSV Treatment Study

Dow Jones
·
Sep 29, 2025

Enanta's RSV treatment misses main goal in mid-stage study

Reuters
·
Sep 29, 2025

BRIEF-Enanta Pharmaceuticals Reports Positive Phase 2b Results for RSV Drug Zelicapavir

Reuters
·
Sep 29, 2025

Enanta Pharmaceuticals Announces Positive Phase 2b Results for Zelicapavir, a Novel Oral RSV Treatment for High-Risk Adults

Reuters
·
Sep 29, 2025

Enanta Pharmaceuticals Inc: Study Showed Zelicapavir Demonstrated Favorable Safety Profile & Was Well-Tolerated

THOMSON REUTERS
·
Sep 29, 2025

Enanta Pharmaceuticals Inc - Lower Hospitalization Rate for Zelicapavir-Treated Patients

THOMSON REUTERS
·
Sep 29, 2025

Enanta Pharmaceuticals Reports Positive Topline Results From Its Phase 2B Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (Rsv) in High-Risk Adults

THOMSON REUTERS
·
Sep 29, 2025

Enanta Pharmaceuticals Announces Topline Results from Phase 2b Study of Zelicapavir for RSV in High-Risk Adults

Reuters
·
Sep 27, 2025

Enanta Pharmaceuticals (ENTA) Receives a Buy from Evercore ISI

TIPRANKS
·
Sep 16, 2025

Enanta Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Sep 15, 2025

Enanta Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Officer Kathleen S. Capps

Reuters
·
Sep 09, 2025

Enanta Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Harry R. Trout III, Vice President, Finance

Reuters
·
Sep 09, 2025